Rani Therapeutics Holdings, Inc. reported its financial results for the second quarter of 2026, revealing a contract revenue of $1.7 million, a significant increase from zero in the same period last year. For the six months ended June 30, 2026, total contract revenue reached $3.4 million, compared to $172,000 in the prior year. The revenue growth is attributed to the Chugai Collaboration and License Agreement, which was established in October 2025. Despite this revenue, the company continues to operate at a loss, with a net loss of $8.4 million for the quarter, a reduction from the $11.2 million loss reported in the same quarter of 2025.
Operating expenses for the second quarter of 2026 were slightly higher at $10.5 million, compared to $10.5 million in the previous year. Research and development expenses decreased by 8.9% to $5.0 million, while general and administrative expenses increased by 10.4% to $5.5 million. The overall loss from operations improved by 16% year-over-year, reflecting the company's efforts to manage costs while advancing its clinical programs.
In terms of operational developments, Rani Therapeutics has made strides in its clinical trials, particularly with the RaniPill HC capsule. The company initiated a Phase 1 clinical trial for RT-114, a bispecific GLP-1/GLP-2 receptor agonist, in December 2025, and recently reported positive initial data from the trial. The oral delivery of RT-114 demonstrated bioavailability exceeding 150% compared to subcutaneous injection, with no serious adverse events reported. This promising data has led to an expansion of the study to further assess dosing.
As of June 30, 2026, Rani Therapeutics had cash, cash equivalents, and marketable securities totaling $53.4 million, a slight increase from $49.7 million at the end of 2025. The company incurred negative cash flows from operations of $15.5 million during the first half of 2026, reflecting ongoing investments in research and development. Rani Therapeutics anticipates continued operating losses as it advances its product candidates and expands its manufacturing capabilities. The company plans to finance its future operations through existing cash reserves and potential strategic financing opportunities, including equity offerings and collaboration agreements.
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics develops oral biotherapeutic delivery platforms, primarily the RaniPill capsule, to administer biologics such as antibodies, peptides, and proteins. Its technology aims to replace injections with convenient oral dosing, targeting markets like obesity, inflammatory diseases, and osteoporosis. The company collaborates with biopharma partners, advancing a pipeline of clinical and preclinical biologic candidates with high bioavailability and precision delivery.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov